I-MAB
IMAB
Company Profile
Business description
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Contact
2440 Research Boulevard
Suite 400
RockvilleMD20850
USAT: +1 240 745-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
220
I-MAB News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,515.20 | 3.70 | -0.04% |
CAC 40 | 7,340.60 | 86.28 | -1.16% |
DAX 40 | 19,227.22 | 221.38 | -1.14% |
Dow JONES (US) | 44,293.13 | 304.14 | 0.69% |
FTSE 100 | 8,080.49 | 44.70 | -0.55% |
HKSE | 19,846.88 | 580.05 | -2.84% |
NASDAQ | 19,298.76 | 11.99 | 0.06% |
Nikkei 225 | 39,376.09 | 157.23 | -0.40% |
NZX 50 Index | 12,749.36 | 63.03 | 0.50% |
S&P 500 | 6,001.35 | 5.81 | 0.10% |
S&P/ASX 200 | 8,255.60 | 10.60 | -0.13% |
SSE Composite Index | 3,421.97 | 48.10 | -1.39% |